Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk
Treatment of hepatitis C (HCV) with direct-acting antiviral agents does not appear to increase the risk of hepatocellular carcinoma (HCC) in individuals with cirrhosis, researchers from France report.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
More News: Antiviral Therapy | Cancer & Oncology | Carcinoma | Cirrhosis | France Health | Health | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | Infectious Diseases | Liver Cancer